Table 1.

Baseline characteristics of TiMM study patients

Category	Characteristic	Aspirin	Apixaban	Total
		n = 4	n = 6	n = 10
Gender	Male sex, n (%)	2 (50)	3 (50)	5 (50)
VTE Risk	Standard	4 (100)	4 (67)	8 (80)
	High	0 (0)	2 (33)	2 (20)
Mean age, years (SD)
		65.0 (8.6)	61.0 (10.5)	63.3 (8.6)
Ethnicity, n (%)
	Black		2 (20)	2 (20)
	White	4 (100)	4 (80)	8 (80)
Weight kg-n (%)	< 70	1 (25)	1 (17)	2 (20)
	70 to ≤ 90	2 (50)	3 (50)	5 (50)
	> 90	1 (25)	2 (33)	3 (30)
Creatinine clearance, mL/min	≥ 80, n (%)	2 (50)	4 (67)	6 (60)
	50 to < 80, n (%)	2 (50)	2 (33)	4 (40
Previous VTE (DVT/PE)				0 (0)
Smoking status
	Never smoker	3 (75)	6 (100)	1 (10)
	Ex-smoker	1 (25)	0 (0)	9 (90)
Myeloma treatment regimen, n (%)
	Velcade/thalidomide/dexamethasone (VTD)	1 (25)	0 (0)	1 (10)
	Carfilzomib/cyclophosphamide/dexamethasone (CCD)	2 (50)	5 (83)	7 (70)
	Velcade/Melphalan/Prenisolone (VMP)	4 (100)	6 (100)	2 (20)
Multiple myeloma classification, n (%)
	Stage 1	2 (50)	3 (50)	5 (50)
	Stage 2	1 (25)	3 (50)	4 (40)
	Stage 3	1 (25)	0 (0)	1 (10)
VTE risk factors, n (%)
	Obesity (BMI > 30)	1 (25)	3 (50)	4 (40)
	Recent surgery (< 6 weeks)	0 (0)	1 (17)	1 (10)